The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding

American Journal of Gastroenterology

Volumn 93, Issue 6, 1998, Pages 962-966

  Hsieh, Wen Jen ^a   Lin, Han Chieh ^a   Hwang, Shinn Jang ^a   Hou, Ming Chih ^a   Lee, Fa Yauh ^a   Chang, Full Young ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFECTION PREVENTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CIPROFLOXACIN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 0032105450     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00288.x     Document Type: Article

References (30)

1. 1. Feliu E, Gougerot MA, Hakim J, et al. Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis. Eur J Clin Invest 1977;7:571-7.
2. 2. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984;4:53-8.
3. 3. Adams HG, Jordan C. Infections in the alcoholic. Med Clin North Am 1984;68:179-200.
4. 4. Rimola A, Arroyo V, Rodes J. Infective complications in acute and chronic liver failure: Basis and control. In: Williams R, ed. Liver failure. Clinics in critical care medicine. London: Churchill Livingstone, 1986:93-111.
5. 5. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8.
6. 6. Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987;28:623-41.
7. 7. Martin WJ, McHenry MC, Wellman WE, et al. Severe liver disease complicated by bacteremia. Arch Intern Med 1962;109:555-62.
8. 8. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial peritonitis: A prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983;3:545-9.
9. 9. Crossley IR, Williams R. Spontaneous bacterial peritonitis. Gut 1985; 26:325-31.
10. 10. Runyon BA. Spontaneous bacterial peritonitis: An explosion of information. Hepatology 1988;8:171-5.
11. 11. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. Hepatology 1988;8:27-31.
12. 12. Bleichner G, Boulanger R, Squara P, et al. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal hemorrhage. Br J Surg 1986;73:724-6.
13. 13. Barnes PF, Arevalo C, Chan LS, et al. A prospective evaluation of bacteremic patients with chronic liver disease. Hepatology 1988;8: 1099-1103.
14. 14. Rimola A, Bory F, Teres J, et al. Oral nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985;5:463-7.
15. 15. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992;103:1267-72.
16. 16. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
17. 17. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
18. 18. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996;111:1011-7.
19. 19. Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988;35:374-447.
20. 20. Smith CR. The adverse effects of fluoroquinolones. J Antimicrob Chemother 1987;20:709-11.
21. 21. Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1985;30:482-513.
22. 22. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial. Hepatology 1995;22:1171-4.
23. 23. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60: 646-9.
24. 24. Blaise M, Pateron D, Trinchet JC, et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994;20:34-8.
25. 25. Pauwels A, Mostefa-Kara N, Debenes B, et al. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996;24:802-6.
26. 26. Bernard B, Cadranel JF, Valla D, et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: A prospective study. Gastroenterology 1995;108:1828-34.
27. 27. Beesen PB, Brannon ES, Warren JV. Observations on the sites of removal of bacteria from the blood in patients with bacterial endocarditis. J Exp Med 1945;81:9-23.
28. 28. Potter BJ, Trueman AM, Jones EA. Serum complement in chronic liver disease. Gut 1973;14:451-6.
29. 29. Berenyi MR, Straus B, Cruz D. In vitro and in vivo studies of cellular immunity in alcoholic cirrhotics. Am J Dig Dis 1974;19:199-205.
30. 30. Lahnborg G, Friman L, Berghem L. Reticuloendothelial function in patients with alcoholic liver cirrhosis. Scand J Gastroenterol 1981;16: 481-9.